华润三九：获创新药铧可思(替洛利生片）中国大陆独占权利

Core Insights - Company Huazhu Sanjiu has signed an agreement with Langyu Group and Bioprojet to obtain exclusive rights for the development, production, and commercialization of the innovative drug "Huakesi (Tilorone Tablets)" in mainland China [1] Group 1: Product and Market Overview - Narcolepsy is recognized globally as a rare disease, with an estimated 3 million patients worldwide and a potential patient population of 300,000 to 700,000 in China [1] - The disease is characterized by chronic neurological symptoms that impair the ability to maintain wakefulness, leading to daytime sleep attacks, cataplexy, hypnagogic hallucinations, and sleep paralysis [1] - The product has been included in the domestic medical insurance system, completed the provincial network work across the country, and entered multiple EDS-related guidelines, providing a safer, more effective, and convenient treatment option for patients [1]